Swedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPP

Swedbank AB bought a new stake in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 113,200 shares of the company’s stock, valued at approximately $3,434,000. Swedbank AB owned 0.24% of Rapport Therapeutics at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in RAPP. Baker BROS. Advisors LP lifted its position in Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after purchasing an additional 997,000 shares during the period. Vestal Point Capital LP acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $28,215,000. Polar Capital Holdings Plc acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $27,887,000. Capital International Investors raised its position in shares of Rapport Therapeutics by 30.7% in the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock valued at $101,055,000 after acquiring an additional 800,000 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Rapport Therapeutics by 265.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company’s stock valued at $26,500,000 after acquiring an additional 648,378 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on RAPP shares. Wall Street Zen upgraded shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Tuesday, April 21st. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a research report on Monday, March 9th. Wells Fargo & Company increased their price target on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Finally, Raymond James Financial started coverage on shares of Rapport Therapeutics in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $66.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rapport Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $58.83.

Insider Activity

In other news, insider Krishnaswamy Yeleswaram sold 20,225 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the completion of the transaction, the insider owned 246,426 shares in the company, valued at $9,854,575.74. This represents a 7.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Rock Ventures V. L.P. Third sold 426,005 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $40.32, for a total transaction of $17,176,521.60. Following the completion of the transaction, the insider owned 6,709,228 shares of the company’s stock, valued at $270,516,072.96. This trade represents a 5.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 878,600 shares of company stock worth $35,223,398 over the last quarter. 13.57% of the stock is currently owned by company insiders.

Rapport Therapeutics Stock Down 0.5%

Rapport Therapeutics stock opened at $39.51 on Thursday. The stock has a market capitalization of $1.89 billion, a PE ratio of -15.20 and a beta of 0.82. Rapport Therapeutics, Inc. has a twelve month low of $7.73 and a twelve month high of $42.27. The company has a 50 day moving average of $34.36 and a 200-day moving average of $30.42.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.14. The company had revenue of $20.00 million during the quarter, compared to analyst estimates of $7.50 million. Equities analysts anticipate that Rapport Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.